EUCTR2015-000804-24-PL进行中（未招募）1 期
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III study to Evaluate the Glycemic Efficacy and Renal Safety of dapagliflozin in patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) who have Inadequate Glycemic Control
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 302
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Female or male aged =18 years and <75 years.
- •2. History of T2DM for more than 12 months.
- •3. Inadequate glycemic control, defined as HbA1c =7.0% and =11%.
- •4. Stable anti-diabetic treatment regimen.
- •5. Renal impairment: CKD 3A.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 151
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 151
排除标准
- •1. Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.
- •2. History of diabetic ketoacidosis or hyperosmolar nonketotic coma.
- •3. Severe uncontrolled hypertension defined as SBP =180 mmHg and/or Diastolic Blood Pressure (DBP) =110 mmHg.
- •4. Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to signing the consent at visit 1:Myocardial infarction, Cardiac surgery or revascularization (CABG/PTCA), Unstable angina, Unstable heart failure (HF), HF New York Heart Association (NYHA) Class IV,Transient ischemic attack (TIA) or significant cerebrovascular disease, Unstable or previously undiagnosed arrhythmia.
- •5. History of any biopsy or imaging verifying intercurrent kidney disease (such as glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis.
- •6. Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency.
- •7. Ongoing treatment with any SGLT2-inhibitor or GLP-1 analogue at screening.
- •8. Participation in another clinical study with an Investigational Product (IP) during the last 30 days prior to signing the consent at visit 1.
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, en pacientes con varias crisis para comparar la eficacia y la seguridad de MK-0974 oral y placebo en el tratamiento agudo de la migraña con o sin aura. - Acute Treatment of Multiple Migraines With or Without Aura in AdultsMigraine MigrañaMedDRA version: 9.1 Level: LLT Classification code 10027599 Term: MigraineEUCTR2007-002667-28-ESMerck Sharp & Dohme de España, S.A.1,834
进行中（未招募）
不适用
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Studyto Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the AcuteTreatment of Migraine With or Without Aura - Acute Treatment of Multiple Migraines With or Without Aura in AdultsMigraineMedDRA version: 9.1Level: LLTClassification code 10027599Term: MigraineEUCTR2007-002667-28-ATMerck Sharp & Dohme GmbH1,834
进行中（未招募）
1 期
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III study to Evaluate the Glycemic Efficacy and Renal Safety of dapagliflozin in patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) who have Inadequate Glycemic ControlEUCTR2015-000804-24-ITAstraZeneca AB321
进行中（未招募）
不适用
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Studyto Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the AcuteTreatment of Migraine With or Without Aura - Acute Treatment of Multiple Migraines With or Without Aura in AdultsMedDRA version: 9.1Level: LLTClassification code 10027599Term: MigraineMigraineEUCTR2007-002667-28-DKMerck & Co. Inc.1,834
进行中（未招募）
不适用
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Studyto Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the AcuteTreatment of Migraine With or Without Aura - Acute Treatment of Multiple Migraines With or Without Aura in AdultsMigraineEUCTR2007-002667-28-SEMerck Sharp & Dohme (Sweden) AB1,834